OMOleg V. Mironov

Oleg V. Mironov

*This is an algorithmically generated author record based on publicly available information.

Oleg V. Mironov has a total of 97 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Clinical and demographic characteristics of patients with advanced HR+/HER2- breast cancer receiving ribociclib combined with endocrine therapy or combination chemotherapy in Russian clinical practice: second interim analysis of the ValerEE study data

    by L. G. Zhukova, E. V. Artamonova, L. Yu. Vladimirova, T. V. Vinogradova, O. V. Mironov, L. M. Voronkova, E. V. Lymar, N. V. Leushina, R. S. Zhikhorev, E. V. Semenov, et al.

    This article presents the results of the second interim analysis of data from the ValerEE study. The analysis examined a population of patients with advanced hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer receiving either ribociclib combined with endocrine therapy (ET) or combination chemotherapy (CT) as first-line treatment in a real-world clinical setting in Russia. The study enrolled 100 % of the planned number of participants (N=333; 188 in the ribociclib plus ET group and 145 in the combination CT group). The groups were balanced regarding age (mean: 59.2 years), body mass index (mean: 27.7), menopausal status (75.7 % postmenopausal), and gender. Statistically significant differences between the groups were identified: the ribociclib plus ET group showed a higher proportion of patients with an ECOG performance status of 0 (20.7 % vs. 9.7 %, p=0.0208) and higher mean expression levels of estrogen receptors (7.4 vs. 6.9, p<0.001) and progesterone receptors (6.2 vs. 4.9, p<0.001); HER2-low status was also more frequent (38.8 % vs. 31.1 %, p=0.0344). Metastatic disease, including locoregional metastases, was more common in the chemotherapy group. The findings indicate that, in standard clinical practice in the Russian Federation, the selection of patients with HR+/HER2- recurrent/metastatic breast cancer for first-line therapy is based on clinical and biological characteristics. These differences must be taken into account when interpreting the comparative efficacy of these approaches.

  • Clinical and demographic characteristics and treatment outcomes of patients with HR+/HER2– advanced breast cancer receiving ribociclib in standard clinical practice in Russia: interim results of the PROSPERITY study

    by E.V. Artamonova, L.YU. Vladimirova, L.G. Zhukova, E.V. Karabina, E.I. Kovalenko, A.V. Shkradyuk, T.V. Vinogradova, R.S. Zhikhorev, Ya.A. Tyugina, D.YU. Yukalchuk, et al.

    Objective. To describe the clinical and demographic characteristics and to assess the effectiveness and safety of ribociclib combined with endocrine therapy (ET) in patients with HR+/HER2– advanced breast cancer (ABC) in Russian clinical practice settings, as part of the PROSPERITY observational study. Materials and methods. At the date of the interim analysis (October 31, 2024), the PROSPERITY study had enrolled 2.390 patients with HR+/HER2– ABC receiving ribociclib, alpelisib, ET, or chemotherapy as part of standard clinical practice in Russia. The ribociclib group comprised 1.468 patients (61.4% of the total cohort). This article analyzes clinical and demographic characteristics, time to treatment failure (TTF), progression-free survival (PFS), overall survival (OS), time to chemotherapy (TTC), and the safety profile of ribociclib. The index date was defined as the date of initiation of ribociclib therapy during the study enrollment period. Results. The median age of patients in the ribociclib arm was 59.0 years. The majority of patients received ribociclib as first-line (63.0%) or second-line (21.9%) therapy. The median TTF was 17.2 months (95% CI 16.1–18.4), and the median PFS was 20.3 months (95% CI 18.8–21.5). Median PFS was 24.3 months for first-line therapy, 16.0 months for second-line, 13.4 months for third-line, and 8.6 months for fourth and subsequent lines. Median OS and median TTC were not reached. Adverse events (AEs) were reported in 47.5% (723/1522) of patients; the most common were neutropenia (16.2%) and leukopenia (7.4%). The rate of treatment discontinuation due to AEs was low (5.9% of all patients in the ribociclib arm). Conclusion. The observational PROSPERITY study provided real-world data from Russia demonstrating ribociclib effectiveness and safety profiles generally comparable to results previously obtained in pivotal clinical trials.

  • Open Access

    The RATIONALE study: Outcomes of targeted therapy for metastatic melanoma in Russia

    by I. V. Samoylenko, K. V. Orlova, N. V. Leushina, A. V. Shkradyuk, O. V. Mironov, I. A. Pokataev, O. O. Shesterikova, O. V. Romachuk, O. A. Snezhko, T. V. Chupriianova, et al.

    Introduction. The efficacy of targeted therapy with the combination of dabrafenib and trametinib in patients with metastatic cutaneous melanoma harboring BRAF mutations has been demonstrated in randomized clinical trials (COMBI-d/v, COMBI-i) and confirmed in real-world clinical practice. The present study aimed to evaluate survival outcomes, tolerability, and treatment modification rates, taking into account the characteristics of clinical practice and the patient population in Russia. The findings are important for optimizing therapeutic strategies and improving the quality of healthcare. Aim. To evaluate the efficacy and safety of dabrafenib plus trametinib in Russian patients with metastatic cutaneous melanoma harboring BRAF V600 mutation in a real-world setting. Materials and methods. RATIONALE is a prospective, non-interventional, multicenter study. A total of 283 patients with unresectable stage IIIC-D and IV melanoma were included. Patients aged ≥ 18 years with metastatic cutaneous melanoma initiated dabrafenib plus trametinib no more than 4 weeks prior to enrolment. The follow-up period was 1 year. Results. Elevated LDH levels were observed in 33.3% of patients, metastases in ≥ 3 organs in 26.5%, and CNS involvement in 18.4%. The 1-year progression-free survival rate was 54% (95% CI: 48–61%), and overall survival was 78% (95% CI: 73–83%). The objective response rate reached 58.0%, with a median time to response of 3.2 months. Adverse events were reported in 35.7% of patients (grade ≥ 3: 12.0%); the most common was pyrexia (16.6%; grade ≥ 3: 4.2%). Treatment discontinuation due to adverse events occurred in 4.6% of patients. Conclusion. In real-world clinical practice, BRAF/MEK targeted therapy has demonstrated effectiveness in the Russian patient population, with outcomes consistent with those observed in randomized clinical trials, despite substantial population heterogeneity and the inclusion of patients with unfavorable prognostic factors.

  • Efficacy of long-term use of atezolizumab in the treatment of metastatic non-small cell lung cancer

    by A.A. Ivannikov, V.D. Sychev, O.V. Mironov, Kh.A. Safaia, O.V. Molotkova, V.A. Tarnavskaya, I.V. Orlov

    Lung cancer is one of the leading oncological diseases in the modern world, and also ranks 1st in terms of mortality. According to statistics, the 5-year survival rate for metastatic lung cancer rarely exceeds 5-10%. The most modern methods of treating non-small cell lung cancer, allowing to achieve the best result, are represented by targeted therapy and immunotherapy with inhibitors of checkpoints of the immune response. The article shows the management tactics of a patient with StIV squamous cell lung cancer (brain) and high PD-L1 expression without activating mutations. After progression on the standard first-line polychemotherapy regimen, atezolizumab was started as the second-line drug therapy. 97 injections of the drug were performed from March 2019 to January 2025. The patient tolerated the therapy satisfactorily. According to control examinations (contrast-enhanced brain MRI, whole-body PET/CT with 18-FDG), a decrease in the size of the tumor focus, a decrease in its metabolic activity, and the disappearance of brain metastases were noted, which indicated the high effectiveness of immunotherapy as an independent treatment for metastatic lung cancer.

  • Open Access

    ORCHIDEA: A Retrospective Study of Patient Demographics, Clinical Characteristics, and Adjuvant Therapy Patterns in Stage II–III HR+/HER2– Breast Cancer Within Routine Clinical Practice

    by Ольга Викторовна Романчук, Денис Юрьевич Юкальчук, Роман Сергеевич Жихорев, Мария Сергеевна Перминова, Сергей Борисович Белоногов, Мария Ивановна Антошкина, Татьяна Валерьевна Гармарник, Надежда Витальевна Леушина, Елена Ивановна Россоха, Ирина Михайловна Радюкова, et al.

    Введение. Риск рецидива гормонозависимого HER2-негативного рака молочной железы (HR+ HER2-РМЖ) II–III стадии сохраняется на протяжении многих лет, несмотря на проводимую комплексную терапию. Оценка факторов риска дает возможность интенсифицировать адъювантную гормонотерапию и предотвратить рецидив. Целью исследования ORCHIDEA являлось определение клинических и демографических характеристик российских пациенток с HR+/HER2-РМЖ II и III стадии, а также оценка назначаемых схем адъювантной терапии в реальной клинической практике. Материалы и методы. Ретроспективное наблюдательное исследование проводили на базе 14 исследовательских центров России. В него включали пациенток старше 18 лет с подтвержденным диагнозом HR+/HER2-РМЖ II–III стадии, получавших адъювантную гормонотерапию в период с 01.12.2022 по 01.12.2023. Результаты. В исследование включили 1000 пациенток. Средний возраст составил 61 год. Пациенты со II стадией достигали 76,1 %. Пациентки без поражения лимфоузлов составляли 42,7 %, из них более половины (64,7 %) имели хотя бы один фактор риска рецидива (Т3–4 или Т2 в сочетании с G3 или с G2 и Ki67 ≥ 20 %); пациентки с поражением одного-трех лимфоузлов (N1) составляли 41,6 %, с N2–3 — 15,7 %. Уровень Ki67 ≥ 20 % отмечался у 61,6 % пациенток; степень злокачественности 3 — у 13 %. Большинство пациенток (73,0 %) получали терапию ингибитором ароматазы (ИА), тамоксифеном — 26,0 %, абемациклибом в сочетании с ИА или тамоксифеном — 1 %. Частота назначения химиотерапии составила 54,8 %: 33,4 % пациентов получали неоадъювантную ХТ, 23,9 % — адъювантную ХТ. Выводы. Исследование выявило ключевые характеристики пациенток с HR+/HER2- РМЖ II–III стадии, позволяя выявить группы высокого риска рецидива и определить необходимость интенсификации терапии. Данные работы создают основу для оптимизации подходов к профилактике рецидивов РМЖ в России.

  • Open Access

    Adjuvant targeted therapy in patients with skin melanoma: evidence from Russian real-world clinical practice (RATIONALE study)

    by Igor V. Samoylenko, Kristina V. Orlova, Denis A. Tantsyrev, Sergey V. Sharov, Alexander V. Sultanbaev, Arshak A. Akopyan, Nadezhda V. Leushina, Akhmed Y. M.Z. Abdelgafur Omar, Ilya A. Pokataev, Tatiana V. Chupriianova, et al.

    Background. Adjuvant targeted therapy (ATT) with a combination of dabrafenib and trametinib after radical surgical treatment in patients with stage III skin melanoma (SM) with a BRAF V600 mutation reduces the risk of disease recurrence. The effectiveness of this approach has been demonstrated in randomized clinical trials, and also confirmed in several large non-Russian real-world (RW) studies. Aim. To evaluate, in RW settings, the effectiveness of ATT with a combination of dabrafenib and trametinib after definitive surgical treatment in patients with BRAF V600-positive SM in Russia. Materials and methods. The RATIONALE study is a prospective, non-interventional, multicenter RW study. The follow-up duration for the study was 1 year. Patients with SM older than 18 years who had previously started dabrafenib and trametinib therapy no more than 8 weeks prior to Visit 1 were included in the study. The paper presents results from the analysis of Cohort 1 only (patients who received dabrafenib and trametinib in the adjuvant setting). Results. The cohort included 214 patients with BRAF V600-mutated SM of stages IIIA–D and IV resectable. At the time of therapy initiation, the majority of patients were stage IIIc (54.7%) or IIIb (22.0%). The most common mutation – BRAF V600E – occurred in 66.3% of cases, while the second most common variant – BRAF V600 not otherwise specified – was detected in 31.3%. One-year overall survival for all included patients was 94%, one-year relapse-free survival was 84%, and one-year distant metastasis-free survival was 86%. No previously listed adverse events were reported. Adverse events led to therapy discontinuation in only 11.7% of cases. ATT did not reduce patients' quality of life. In the subgroup analysis, the effectiveness of the combination of dabrafenib and trametinib after removal of distant metastases (equivalent to stage IV resectable) was found, in particular, the one-year relapse-free survival rate was 83%, and the one-year overall survival rate was 100%, which is comparable to these indicators for stage IIIB-D (72–86 and 78–100%, respectively). Conclusion. The effectiveness and favorable safety profile of the combination of dabrafenib and trametinib in ATT after radical surgical treatment was confirmed in a population of Russian patients with SM in the RW settings.